Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

  • This share is currently suspended. It was suspended at a price of 0.225

Share Price Information for Kanabo Grp Plc (KNB)

Share Price is delayed by 15 minutes
Get Live Data
0.225    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £1.42m
KNB Live PriceLast checked at - London Stock Exchange

Intraday Kanabo Grp Plc Share Chart

New Subsidiary

16 Jun 2022 07:00

RNS Number : 0395P
Kanabo Group PLC
16 June 2022
 

Kanabo Group Plc.

("Kanabo" or the "Company")

 

New Subsidiary

 

First MoU for an Indoor Medical Cannabis Production Facility in Spain

 

Kanabo Group Plc. (LON: KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, announces it has formed a new, partly owned, subsidiary to monetise the Company's Intellectual Property and that the new subsidiary has signed its first Memorandum of Understanding ("MoU") for an indoor medical cannabis cultivation project in Spain.

 

Kanabo Agritec Ltd

Kanabo Group plc has formed an Israeli subsidiary company, Kanabo Agritec Ltd. ("Agritec"), which Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group plc., holds a 40% shareholding together with certain additional control rights over the strategic direction of the subsidiary

 

Agritec's sole purpose is to enter into agreements with third parties at minimal cost to leverage the Company's Intellectual Property for the cultivation, processing, and production of cannabis products.

 

The strategic rationale for Kanabo is twofold:

· Firstly, Agritec provides Kanabo with complementary near-term revenue opportunities

· Secondly, Agritec will offer Kanabo improved security of cannabis supply through a diverse range of suppliers, who will all adopt Kanabo's high-quality manufacturing standards without Kanabo having to fund or become directly involved in cannabis cultivation.

 

Agritec's three other shareholders are co-founders Ophir Shimshi and Eilon Bdil, experts in Cannabis regulation and cultivation and R. P. Growing Technologies Ltd., who each hold 20% of the issued share capital in Agritec.

 

R.P. Growing Technologies Ltd, is a Group of companies, which includes Grow Tec Innovations Ltd (2018) & We Can Dry Ltd (2018), which are both experienced in agricultural technology projects, providing a wide range of services, from planning, designing, engineering and/or manufacturing as well as complete turnkey projects and high-level agricultural projects in field of medical Cannabis.

 

Agritec, will be able to offer customers turnkey consulting services relating to the:

· Procurement, design and build of commercial scale medical cannabis cultivation facilities

· Supply high-quality genetics and standard operating procedures for optimal medical cannabis cultivation

· Provide post-harvest services including offtake agreements with Kanabo Group plc

· Design and draft reporting and documentation filing services with the local authorities

· Provide local training and ongoing consulting services

 

First MoU for a 4,000kg Indoor Medical Cannabis Production Project in Spain

Agritec has signed its first MoU for the design, build and operation of a 4,000kg per annum indoor cultivation and processing facility in Madrid, Spain. The proposed facility is to be focused exclusively on medical cannabis.

 

As per the terms of the MoU, Agritec may may elect to receive up to 20% ownership of the Project based on the achievement of agreed milestones.

 

 

 

For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:

 

Kanabo Group Plc

Via Vox Markets

Avihu Tamir, CEO

Peterhouse Capital Ltd (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Lauren Riley

Vox Markets (Investor Relations)

KanaboGroup@voxmarkets.co.uk

Kat Perez

kperez@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.

 

The Company has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKPBQPBKDCAD
Date   Source Headline
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021
4th Nov 20217:00 amRNSUpdate on Materia Acquisition
29th Oct 20217:00 amRNSTotal Voting Rights
22nd Oct 20217:00 amRNSHalf-year Report
7th Oct 20217:00 amRNSNew Partnership Agreement
30th Sep 20217:00 amRNSTotal Voting Rights
22nd Sep 20217:00 amRNSCBD Line Launched in the UK on HandpickedCBD.com
14th Sep 20217:05 amRNSMateria Receives Licence for Malta Facility
31st Aug 20211:51 pmRNSTotal Voting Rights
17th Aug 202111:05 amRNSSecond Price Monitoring Extn
17th Aug 202111:00 amRNSPrice Monitoring Extension
17th Aug 20217:00 amRNSUpdate: New contract signed by Materia
2nd Aug 20217:01 amRNSUpdate re: Investment & MoU with Hellenic Dynamics
30th Jul 202112:49 pmRNSTotal Voting Rights
26th Jul 202111:05 amRNSSecond Price Monitoring Extn
26th Jul 202111:00 amRNSPrice Monitoring Extension
26th Jul 20217:00 amRNSProposed Acquisition
22nd Jul 20213:32 pmRNSBlock Listing Application
14th Jul 20217:00 amRNSKanabo’s First Medical Cannabis Product in UK
8th Jul 20211:00 pmRNSIssue of Equity
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20217:00 amRNSAppointment of Director & Grant of Options
28th Jun 20213:41 pmRNSResult of AGM
25th Jun 20217:00 amRNSInitial Commercial Scale Production
24th Jun 20213:58 pmRNSIssue of Equity
17th Jun 20212:59 pmRNSIssue of Equity
4th Jun 20217:00 amRNSSupport for New Campaign
3rd Jun 202112:00 pmRNSNotice of AGM
2nd Jun 20219:26 amRNSAnnual Financial Report
26th May 20213:36 pmRNSAdmission of Placing Shares
24th May 20217:00 amRNSPlacing, Investment & MoU with Hellenic Dynamics
20th May 20217:00 amRNSNew EU GMP CBD Manufacturing Agreement
14th May 20212:00 pmRNSIssue of Equity
11th May 20211:09 pmRNSIssue of Equity
6th May 20212:00 pmRNSIssue of Equity
26th Apr 20213:03 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.